Bill · S. 4327· Senate(119-S-4327)
Securing America’s Drug Supply from Communist China Act
- Introduced
- 4/16/2026
- Last activity
- 4/16/2026 — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Sponsored by
- Tom Cotton
- Cosponsors
- - 1 - 0
- Introduced
- In Committee
What this bill would do
The Securing America's Drug Supply from Communist China Act requires a regulatory review of pharmaceutical products from Chinese entities. The Secretary of Health and Human Services, working with the Office of National Security, will review drug applications to determine if sponsors are affiliated with the PRC, CCP, or PLA. If an application is submitted on or after enactment by a Chinese entity or a licensee of one, the Secretary may deny approval if the sponsor is found to be a PRC-, CCP-, or PLA-affiliated entity. The bill also mandates a review of certain applications submitted between January 1, 2016, and the date of enactment. Additionally, it directs the refusal and destruction of drugs imported by such affiliated entities, unless a waiver is granted due to drug shortages.
Yes
Does this better protect the country from computer attacks?+1
The bill addresses potential national security risks associated with foreign-controlled pharmaceutical entities.
The opposite
Does this make health care easier to get in general?-2
The bill could restrict the supply of certain medications by refusing and destroying imports from affiliated entities.
Would business owners be better off under this?-1
The regulatory burden and potential loss of assets via destruction of imported drugs could negatively impact pharmaceutical business owners.
Does this make it easier to run a small business?-1
The bill imposes regulatory barriers and potential destruction of goods that could impact businesses involved in the pharmaceutical supply chain.
Who it would affect, and how
Potential Positive Impacts for People
-
Drug Shortage Protection: The Commissioner of U.S. Customs and Border Protection may waive the refusal of imports if the Secretary determines that refusing the drug would create or exacerbate a drug shortage in the United States (Section 2(d)(4)).
-
Opportunity for Compliance or Sale: Entities found to be affiliated may have a process to demonstrate they are no longer such an entity or may sell their approved drug application to a non-affiliated entity within 180 days (Section 2(d)(3)(A)).
Potential Negative Impacts for People
-
Denial of Drug Applications: The Secretary is prohibited from approving drug applications submitted on or after the date of enactment if the sponsor is determined to be a PRC-, CCP-, or PLA-affiliated entity (Section 2(b)(2)).
-
Refusal and Destruction of Imported Drugs: Drugs offered for import that are sponsored or held by a determined PRC-, CCP-, or PLA-affiliated entity shall be refused and destroyed by U.S. Customs and Border Protection without the opportunity for export (Section 2(d)(2)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Healthcare
- Improves Healthcare Access-2
- Demographic And Interest Groups
- Good For Business Owners-1
- Economy And Finance
- Improves Small Business Support-1
- National Security And Foreign Policy
- Improves Cybersecurity Defense+1
- 8/4/2026
- 1 Cosponsor added.
- 4/16/2026
- Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Introduced in Senate
Jim BanksRepublican · Indiana